---
document_datetime: 2025-12-02 05:04:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-viatris.html
document_name: olanzapine-viatris.html
version: success
processing_time: 0.1264054
conversion_datetime: 2025-12-28 01:56:20.196318
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Olanzapine Viatris (previously Olanzapine Mylan)

[RSS](/en/individual-human-medicine.xml/66778)

##### Authorised

This medicine is authorised for use in the European Union

olanzapine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Olanzapine Mylan](#more-information-on-olanzapine-mylan-1420)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Olanzapine Viatris is used to treat adults with schizophrenia. Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (seeing, hearing or feeling things that are not there).

Olanzapine Viatris is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence (when symptoms come back) of these episodes in adults with bipolar disorder (a mental illness with alternating periods of high mood and depression) who have responded to an initial course of treatment.

Olanzapine Viatris contains the active substance olanzapine and is a 'generic medicine'. This means that Olanzapine Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Olanzapine Viatris is Zyprexa. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Olanzapine Viatris used?

Olanzapine Viatris is available as tablets and is taken once a day. The dose depends on the disease being treated and may be adjusted depending on how well the patient responds to and tolerates the treatment.

The medicine can only be obtained with a prescription.

For more information about using Olanzapine Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Olanzapine Viatris work?

The active substance in Olanzapine Viatris, olanzapine, is an antipsychotic medicine. It is known as an 'atypical' antipsyc h otic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other.

It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

## How has Olanzapine Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Zyprexa, and do not need to be repeated for Olanzapine Viatris.

As for every medicine, the company provided studies on the quality of Olanzapine Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Olanzapine Viatris?

Because Olanzapine Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Olanzapine Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Olanzapine Viatris has been shown to have comparable quality and to be bioequivalent to Zyprexa. Therefore, the Agency's view was that, as for Zyprexa, the benefits of Olanzapine Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Olanzapine Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Olanzapine Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Zyprexa also apply to Olanzapine Viatris where appropriate.

As for all medicines, data on the use of Olanzapine Viatris are continuously monitored. Suspected side effects reported with Olanzapine Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Olanzapine Viatris

Olanzapine Mylan received a marketing authorisation valid throughout the EU on 7 October 2008.

The name of the medicine was changed to Olanzapine Viatris on 15 October 2024.

Olanzapine Viatris : EPAR - Medicine overview

Reference Number: EMA/536711/2024

English (EN) (135.87 KB - PDF)

**First published:** 16/10/2008

**Last updated:** 27/01/2025

[View](/en/documents/overview/olanzapine-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-811)

български (BG) (163.09 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/bg/documents/overview/olanzapine-viatris-epar-medicine-overview_bg.pdf)

español (ES) (138.04 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/es/documents/overview/olanzapine-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (159.7 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/cs/documents/overview/olanzapine-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (136.73 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/da/documents/overview/olanzapine-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (140.74 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/de/documents/overview/olanzapine-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (135.35 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/et/documents/overview/olanzapine-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (162.63 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/el/documents/overview/olanzapine-viatris-epar-medicine-overview_el.pdf)

français (FR) (139.48 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/fr/documents/overview/olanzapine-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (157.11 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/hr/documents/overview/olanzapine-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (137.35 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/it/documents/overview/olanzapine-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (177.17 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/lv/documents/overview/olanzapine-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (159.07 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/lt/documents/overview/olanzapine-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (159.64 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/hu/documents/overview/olanzapine-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (161.64 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/mt/documents/overview/olanzapine-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (137.91 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/nl/documents/overview/olanzapine-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (162.66 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/pl/documents/overview/olanzapine-viatris-epar-medicine-overview_pl.pdf)

português (PT) (113.38 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/pt/documents/overview/olanzapine-viatris-epar-medicine-overview_pt.pdf)

română (RO) (156.33 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/ro/documents/overview/olanzapine-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (158.99 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/sk/documents/overview/olanzapine-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (156.25 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/sl/documents/overview/olanzapine-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (135.25 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/fi/documents/overview/olanzapine-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (135.21 KB - PDF)

**First published:**

16/10/2008

**Last updated:**

27/01/2025

[View](/sv/documents/overview/olanzapine-viatris-epar-medicine-overview_sv.pdf)

## Product information

Olanzapine Viatris : EPAR - Product information

English (EN) (445.21 KB - PDF)

**First published:** 25/11/2009

**Last updated:** 13/01/2025

[View](/en/documents/product-information/olanzapine-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-902)

български (BG) (854.48 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/bg/documents/product-information/olanzapine-viatris-epar-product-information_bg.pdf)

español (ES) (369.23 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/es/documents/product-information/olanzapine-viatris-epar-product-information_es.pdf)

čeština (CS) (606.9 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/cs/documents/product-information/olanzapine-viatris-epar-product-information_cs.pdf)

dansk (DA) (675.94 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/da/documents/product-information/olanzapine-viatris-epar-product-information_da.pdf)

Deutsch (DE) (531.99 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/de/documents/product-information/olanzapine-viatris-epar-product-information_de.pdf)

eesti keel (ET) (430.8 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/et/documents/product-information/olanzapine-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (540.19 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/el/documents/product-information/olanzapine-viatris-epar-product-information_el.pdf)

français (FR) (697 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/fr/documents/product-information/olanzapine-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (467.37 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/hr/documents/product-information/olanzapine-viatris-epar-product-information_hr.pdf)

íslenska (IS) (631.98 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/is/documents/product-information/olanzapine-viatris-epar-product-information_is.pdf)

italiano (IT) (361.97 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/it/documents/product-information/olanzapine-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (465.78 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/lv/documents/product-information/olanzapine-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (473.59 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/lt/documents/product-information/olanzapine-viatris-epar-product-information_lt.pdf)

magyar (HU) (725.78 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/hu/documents/product-information/olanzapine-viatris-epar-product-information_hu.pdf)

Malti (MT) (900.99 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/mt/documents/product-information/olanzapine-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (569.6 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/nl/documents/product-information/olanzapine-viatris-epar-product-information_nl.pdf)

norsk (NO) (658 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/no/documents/product-information/olanzapine-viatris-epar-product-information_no.pdf)

polski (PL) (454.78 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/pl/documents/product-information/olanzapine-viatris-epar-product-information_pl.pdf)

português (PT) (502.58 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/pt/documents/product-information/olanzapine-viatris-epar-product-information_pt.pdf)

română (RO) (616.29 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/ro/documents/product-information/olanzapine-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (627.93 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/sk/documents/product-information/olanzapine-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (423.79 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/sl/documents/product-information/olanzapine-viatris-epar-product-information_sl.pdf)

Suomi (FI) (645.68 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/fi/documents/product-information/olanzapine-viatris-epar-product-information_fi.pdf)

svenska (SV) (611.37 KB - PDF)

**First published:**

25/11/2009

**Last updated:**

13/01/2025

[View](/sv/documents/product-information/olanzapine-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0061 19/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Olanzapine Viatris : EPAR - All authorised presentations

English (EN) (50.73 KB - PDF)

**First published:** 19/12/2008

**Last updated:** 17/10/2024

[View](/en/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-732)

български (BG) (35.63 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/bg/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.08 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/es/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.39 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/cs/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (68.86 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/da/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (38.95 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/de/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.34 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/et/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (94.26 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/el/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (28.62 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/fr/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (125.33 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/hr/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (72.1 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/is/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (123.51 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/it/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (81.06 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/lv/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (83.77 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/lt/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.31 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/hu/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.72 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/mt/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (65.7 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/nl/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (65.81 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/no/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.34 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/pl/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (63.25 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/pt/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.2 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/ro/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.25 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/sk/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (77.59 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/sl/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (91.82 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/fi/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (92.4 KB - PDF)

**First published:**

19/12/2008

**Last updated:**

17/10/2024

[View](/sv/documents/all-authorised-presentations/olanzapine-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Olanzapine Viatris (previously Olanzapine Mylan) Active substance olanzapine International non-proprietary name (INN) or common name olanzapine Therapeutic area (MeSH)

- Schizophrenia
- Bipolar Disorder

Anatomical therapeutic chemical (ATC) code N05AH03

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

**Adults**

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

## Authorisation details

EMA product number EMEA/H/C/000961

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin Dublin 15 Ireland

Marketing authorisation issued 06/10/2008 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Olanzapine Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (220.9 KB - PDF)

**First published:** 25/11/2009

**Last updated:** 13/01/2025

[View](/en/documents/procedural-steps-after/olanzapine-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Olanzapine Mylan : EPAR - Public assessment report

English (EN) (187.01 KB - PDF)

**First published:** 16/10/2008

**Last updated:** 16/10/2008

[View](/en/documents/assessment-report/olanzapine-mylan-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Olanzapine Mylan

Reference Number: EMEA/CHMP/376249/2008

English (EN) (32.68 KB - PDF)

**First published:** 24/07/2008

**Last updated:** 24/07/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-olanzapine-mylan_en.pdf)

#### More information on Olanzapine Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/01/2025

## Share this page

[Back to top](#main-content)